Kemwell Biopharma will offer services ranging from full-service process development, manufacture, formulation and fill & finish at the cGMP manufacturing facility in Bangalore, India as a one-stop-shop through access to Boehringer Ingelheim's® cell line development with the BI HEX technology platform, followed by a preferred access to the large-scale commercial production of Boehringer Ingelheim at its facilities in Europe. With this cooperation, Kemwell and Boehringer Ingelheim will provide the customer with state-of-the-art technology from Europe along with the benefit of low cost manufacturing from India.
Process technology will originate from Boehringer Ingelheim and equipments in upstream and downstream in the new facility will comply with Boehringer Ingelheim's manufacturing technology. This will ensure seamless and quick technology transfer and scale-up between Kemwell's small scale and Boehringer Ingelheim's large scale manufacturing facility to reduce time to market for the customer.
The new Kemwell Biopharma 15,000 sq mt facility will be designed for process development, production, purification and formulation of biologics for early-phase preclinical and clinical studies. The facility will consist of a cGMP drug substance manufacturing facility and a sterile fill and finish facility for drug product with a floor for process development laboratories to support production of protein therapeutics from mammalian-cell culture or microbial fermentation.